Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016

被引：39

作者：

Chambers, C. ^{[1
]}

Skowronski, D. M. ^{[1
,2
]}

Sabaiduc, S. ^{[1
]}

Winter, A. L. ^{[3
]}

Dickinson, J. A. ^{[4
]}

De Serres, G. ^{[5
,6
,7
]}

Gubbay, J. B. ^{[3
,8
]}

Drews, S. J. ^{[9
,10
]}

Martineau, C. ^{[5
]}

Eshaghi, A. ^{[3
]}

Krajden, M. ^{[1
,2
]}

Bastien, N. ^{[11
]}

Li, Y. ^{[11
,12
]}

机构：

[1] British Columbia Ctr Dis Control, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[3] Publ Hlth Ontario, Toronto, ON, Canada

[4] Univ Calgary, Calgary, AB, Canada

[5] Inst Natl Sante Publ Quebec, Natl Inst Hlth Quebec, Quebec City, PQ, Canada

[6] Univ Laval, Quebec City, PQ, Canada

[7] Univ Hosp Ctr Quebec, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada

[8] Univ Toronto, Toronto, ON, Canada

[9] Alberta Prov Lab, Edmonton, AB, Canada

[10] Univ Alberta, Edmonton, AB, Canada

[11] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada

[12] Univ Manitoba, Winnipeg, MB, Canada

来源：

EUROSURVEILLANCE | 2016年 / 21卷 / 11期

关键词：

TEST-NEGATIVE DESIGN; SURVEILLANCE; HEMAGGLUTININ;

D O I：

10.2807/1560-7917.ES.2016.21.11.30168

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2015/16 vaccine effectiveness (VE) against influenza A(H1N1) pdm09 viruses. Adjusted VE showed significant protection of 64% (95% confidence interval (CI): 44-77%) overall and 56% (95% CI: 26-73%) for adults between 20 and 64 years-old against medically attended, laboratory-confirmed A(H1N1) pdm09 illness. Among the 67 A(H1N1) pdm09-positive specimens that were successfully sequenced, 62 (> 90%) belonged to the emerging genetic 6B.1 subclade, defined by S162N (potential gain of glycosylation) and I216T mutations in the haemagglutinin protein. Findings from the Canadian SPSN indicate that the 2015/16 northern hemisphere vaccine provided significant protection against A(H1N1) pdm09 illness despite genetic evolution in circulating viruses.

引用

页码：27 / 34

页数：8

共 29 条

[1]

[Anonymous], 2016, REC COMP INFL VIR VA

[2]

[Anonymous], REC VIR INFL VACC US

[3]

Appiah GD, 2015, MMWR-MORBID MORTAL W, V64, P583

[4]

Belongia EA, 2016, LANCET INFE IN PRESS

[5] The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin [J].

Brownlee, GG ;

Fodor, E .

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 2001, 356 (1416) :1871-1876

[6]

De Serres G, 2013, Euro Surveill, V18

[7]

European Centre for Disease Prevention and Control, 2016, INFL VIR CHAR SUMM E

[8] Influenza vaccine effectiveness by test-negative design - Comparison of inpatient and outpatient settings [J].

Feng, Shuo ;

Cowling, Benjamin J. ;

Sullivan, Sheena G. .

VACCINE, 2016, 34 (14) :1672-1679

[9] The case test-negative design for studies of the effectiveness of influenza vaccine [J].

Foppa, Ivo M. ;

Haber, Michael ;

Ferdinands, Jill M. ;

Shay, David K. .

VACCINE, 2013, 31 (30) :3104-3109

[10]

Gaglani M, 2016, J INFECT DIS

← 1 2 3 →